Crucell calls meeting on J&J bid; GSK to ramp up in India, S. Africa for donated pill;

 @FiercePharma: Sanofi $69 offer hits Termeer's personal wallet. Report | Follow @FiercePharma 

> Dutch biotech firm Crucell (CRCL.AS) said it would hold an extraordinary shareholders' meeting on Dec. 10 to discuss investors' objections to an agreed buyout bid from Johnson & Johnson (JNJ.N). Report

> To fulfill its donation pledge of 1 billion anti-parasite tablets per year, GlaxoSmithKline (GSK) is beefing up production of the drug, albendazole, in India and South Africa. News

> Labopharm expanded a deal that gives Paladin Labs the right to sell its pain treatments, extending the arrangement to cover an additional drug in Canada and several more in Africa. Story

> The European Medicines Agency has published new rules on how it will be handling potential conflicts of interests of panellists on its committees. Report

> Cubist Pharmaceuticals (CBST.O) posted lower-than-expected quarterly revenue on slowing growth of its lead antibiotic Cubicin, and narrowed its full-year revenue view. News

> A shareholder in Dutch biotech Crucell (CRCL.AS), subject to an agreed bid by U.S.-based Johnson & Johnson (JNJ.N), has sold all its shares in the firm, underlining market doubts that a higher buyout offer will emerge. Article

> Reckitt Benckiser was fined 10.2 million pounds ($16.4 million) by a U.K. regulator for wrongfully stopping supplies of a heartburn medicine to the National Health Service after its patent expired. Article

> New Horizon Capital, a private equity firm co-founded by the son of Chinese Premier Wen Jiabao, has bowed out as an investor of Sihuan Pharmaceutical ahead of the drug maker's planned listing later this month. Item

Biotech News:

 @FierceBiotech: Genzyme sees signs of remission in 5-year MS drug data. Report | Follow @FierceBiotech

 @JohnCFierce: FDA's Top Q4 Blockbuster Drug Decisions | Follow @JohnCFierce

> VC investing declines in Q3, but biotech sees bump. Story

> Following Biogen deal, Knopp forms parent company. Report

> Myriad Genetics' shares rise on takeover talk. News

> SurModics cuts 13% of staff in reorg. News

And Finally... Diet drugs for humans aren't the only variety to be dogged by safety issues: FDA is examining whether some dog breeds are genetically predisposed to side effects from a canine anti-obesity treatment sold by Pfizer. Report